Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.51)
# 803
Out of 5,182 analysts
212
Total ratings
47.29%
Success rate
20.41%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $5.79 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $22.20 | +26.15% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $186.95 | -19.76% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $168.51 | -9.20% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $14.57 | -3.91% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $71.46 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $9.80 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $32.74 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $27.74 | +109.08% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $34.84 | +23.42% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $66.73 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.86 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $131.60 | +17.78% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.90 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $20.65 | +69.49% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $7.00 | +85.71% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.87 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.79 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $24.69 | +37.71% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $37.23 | +34.30% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $7.49 | -33.24% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.14 | +250.88% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $56.85 | +2.02% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.42 | +77,364.79% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.12 | +1,462.50% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.41 | +112.77% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $2.99 | +267.89% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $6.42 | +86.92% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $7.70 | +2,081.82% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.43 | +483.09% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $41.17 | +385.79% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $2.20 | +81.82% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.13 | +12,643.36% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.66 | +140.96% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $64.49 | -39.53% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $42.49 | -64.70% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.30 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.34 | +5,289.22% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.79
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $22.20
Upside: +26.15%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $186.95
Upside: -19.76%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $168.51
Upside: -9.20%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $14.57
Upside: -3.91%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $71.46
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.80
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.74
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $27.74
Upside: +109.08%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $34.84
Upside: +23.42%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $66.73
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.86
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $131.60
Upside: +17.78%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.90
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $20.65
Upside: +69.49%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $7.00
Upside: +85.71%
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.87
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.79
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $24.69
Upside: +37.71%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $37.23
Upside: +34.30%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $7.49
Upside: -33.24%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.14
Upside: +250.88%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $56.85
Upside: +2.02%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.42
Upside: +77,364.79%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.12
Upside: +1,462.50%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.41
Upside: +112.77%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $2.99
Upside: +267.89%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.42
Upside: +86.92%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $7.70
Upside: +2,081.82%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $3.43
Upside: +483.09%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $41.17
Upside: +385.79%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $2.20
Upside: +81.82%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.13
Upside: +12,643.36%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.66
Upside: +140.96%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $64.49
Upside: -39.53%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $42.49
Upside: -64.70%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.30
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $3.34
Upside: +5,289.22%